Results 51 to 60 of about 355,709 (346)

KRAS in NSCLC: State of the Art and Future Perspectives

Cancers, 2022
Simple Summary Rat sarcoma virus (RAS) GTP-ase proteins represent a key element in cellular proliferation, growth, and differentiation. Three different isoforms of RAS proteins have been identified to date (KRAS, NRAS, HRAS) and mutations in KRAS are ...
Priscilla Cascetta, A. Marinello, C. Lazzari, V. Gregorc, D. Planchard, R. Bianco, N. Normanno, A. Morabito   +7 more
semanticscholar   +1 more source

lncRNA SLC9A3-AS1 Promotes Oncogenesis of NSCLC via Sponging microRNA-760 and May Serve as a Prognosis Predictor of NSCLC Patients

Cancer Management and Research, 2022
Xiuming Huang,* Mingfang Huang,* Minbiao Chen, Xianshan Chen Department of Thoracic Surgery, Hainan General Hospital, Haikou, Hainan, 570311, People’s Republic of China*These authors contributed equally to this workCorrespondence: Xianshan ...
Huang X, Huang M, Chen M, Chen X
doaj  

Histone Modification in NSCLC: Molecular Mechanisms and Therapeutic Targets

International Journal of Molecular Sciences, 2021
Lung cancer is the leading cause of cancer mortality in both genders, with non-small cell lung cancer (NSCLC) accounting for about 85% of all lung cancers.
K. Bajbouj, A. Al-Ali, R. Ramakrishnan, M. Saber-Ayad, Q. Hamid   +4 more
semanticscholar   +1 more source

Clinical Significance of miR-183-3p and miR-182-5p in NSCLC and Their Correlation

Cancer Management and Research, 2021
Tianxiang Zhang,1 Wei Li,2 Meng Gu,1 Ziyu Wang,1 Shijie Zhou,2 Xuefeng Hao,1 Weiying Li,1 Shaofa Xu1 1Department of Cellular and Molecular Biology, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis and Thoracic Tumor Research ...
Zhang T, Li W, Gu M, Wang Z, Zhou S, Hao X, Li W, Xu S   +7 more
doaj  

The HDAC inhibitor GCJ-490A suppresses c-Met expression through IKKα and overcomes gefitinib resistance in non-small cell lung cancer

Cancer Biology & Medicine, 2022
Objective: The novel compound GCJ-490A has been discovered as a pan-histone deacetylase (HDAC) inhibitor that exerts potent inhibitory activity against HDAC1, HDAC3, and HDAC6.
Ting He, Yinglei Gao, Yanfen Fang, Yangming Zhang, Shuwei Zhang, Fajun Nan, Jian Ding, Yi Chen   +7 more
doaj   +1 more source

m6A demethylase ALKBH5 inhibits tumor growth and metastasis by reducing YTHDFs-mediated YAP expression and inhibiting miR-107/LATS2–mediated YAP activity in NSCLC

Molecular Cancer, 2020
The importance of mRNA methylation erased by ALKBH5 in mRNA biogenesis, decay, and translation control is an emerging research focus. Ectopically activated YAP is associated with the development of many human cancers.
Dan-ting Jin, Jiwei Guo, Yan Wu, Lijuan Yang, Xiaohong Wang, Jing Du, Juanjuan Dai, Weiwei Chen, Kaikai Gong, Shuang Miao, Xuelin Li, Hongliang Sun   +11 more
semanticscholar   +1 more source

GBP5 Identifies Immuno-Hot Tumors and Predicts the Therapeutic Response to Immunotherapy in NSCLC

International Journal of General Medicine, 2023
Honghong Fan,* Yuxin Shi,* Huiyu Wang, Yuting Li, Jie Mei, Junying Xu, Chaoying Liu Department of Oncology, The Affiliated Wuxi People’s Hospital of Nanjing Medical University, Wuxi, Jiangsu, 214023, People’s Republic of China*These authors ...
Fan H, Shi Y, Wang H, Li Y, Mei J, Xu J, Liu C   +6 more
doaj  

Neoadjuvant Chemoimmunotherapy for NSCLC

JAMA Oncology
This meta-analysis investigates the association of neoadjuvant chemoimmunotherapy with patient benefits vs neoadjuvant chemotherapy in patients with non–small cell lung cancer (NSCLC).
M. Sorin, Connor Prosty, Louis Ghaleb, Kathy Nie, Khaled Katergi, Muhammad H. Shahzad, Laurie-Rose Dubé, Aline Atallah, Anikka M Swaby, M. Dankner, Trafford Crump, L. Walsh, P. Fiset, B. Sepesi, P. Forde, T. Cascone, Mariano Provencio, Jonathan D Spicer   +17 more
semanticscholar   +1 more source

Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001

Annals of Oncology, 2019
Background In the ongoing phase I PROFILE 1001 study, crizotinib showed antitumor activity in patients with ROS1-rearranged advanced non-small-cell lung cancer (NSCLC).
A. Shaw, Gregory Riely, Y. Bang, D. Kim, D. Camidge, B. Solomon, M. Varella-Garcia, A. Iafrate, G. Shapiro, T. Usari, S. C. Wang, K. Wilner, J. Clark, S. Ou   +13 more
semanticscholar   +1 more source

Circular RNA circ-CPA4/ let-7 miRNA/PD-L1 axis regulates cell growth, stemness, drug resistance and immune evasion in non-small cell lung cancer (NSCLC)

Journal of experimental & clinical cancer research : CR, 2020
Non-small cell lung cancer (NSCLC) cells derived intracellular and extracellular programmed cell death ligand 1 (PD-L1) promoted cancer progression and drug resistance, and facilitated tumor immune evasion.
Weijun Hong, M. Xue, Jun Jiang, Yajuan Zhang, Xiwen Gao   +4 more
semanticscholar   +1 more source